home.aspx
 
EVENTS

Update CME - Internal Medicine & Primary Care
UPDATE CME - INTERNAL MEDICINE & PRIMARY CARE
October 29-01, 2020
Earn 30 CME Credits by attending our Update CME Internal Medicine and Primary Care Conference either in person or via live stream!Expert speakers from The University of Chicago, Johns Hopkins, and University of California, Los Angeles will be presenting on the latest clinical guidelines. We offer in...

Vital Signs EMS Conference
VITAL SIGNS EMS CONFERENCE
October 29-01, 2020
Vital Signs EMS Conference will be showcasing many of the extraordinary aspects of EMS and healthcare found only in Saratoga Springs. This event provided high quality and cutting edge EMS education by providing access to national and world-renowned educators through a forum that is accessible and af...

Colorcon

SHARESHARESHARE
Colorcon is a world leader in the development, supply and technical support of formulated film coating systems, modified release technologies, and functional excipients for the pharmaceutical and nutritional industries. Our best-in-class products and technologies are complemented by our extensive application data and value-added services to support all phases of solid oral dose design, development and manufacture. Our focus on market issues and technology development has earned Colorcon an international reputation as a pharmaceutical supplier of choice. That reputation is based on superior product quality, unparalleled technical support, extensive regulatory assistance and reliable supply from multiple locations.
SHARESHARESHARE

RELATED NEWS


Merck KGaA wants to get bigger in immuno-oncology, but from now on it won’t be taking a direct role in the drive to develop new CAR-T therapies. The German drugmaker has reached an agreement to transfer all rights to its CAR-T technology and development programmes to US biotech company Intrexon in return for a $150 million equity stake in the Maryland-based firm, plus a note for another $25 million in stock. Merck is also giving Intrexon $25 million in cash to help get the CAR-T programmes...

READ MORE

ForwardVue Pharma has secured initial seed round funding in order to advance pre-clinical development of potent long acting anti-angiogenic molecules directed against diabetic eye disease and neovascular age related macular degeneration. As the Founder of ForwardVue Pharma, Alan has performed 40,000+ intravitreal injections as a practicing retina specialist with over 20 years of experience. He has served as principle investigator in a number of diabetic retinopathy and AMD trials, presents his w...
PRNEWSWIRE
READ MORE

onis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that the U.S. Food and Drug Administration (FDA) has approved SPINRAZATM (nusinersen) under Priority Review for the treatment of spinal muscular atrophy (SMA) in pediatric and adult patients. SPINRAZA is the first and only treatment approved in the U.S. for SMA, a leading genetic cause of death in infants and toddlers that is marked by progressive, debilitating muscle weakness. SPINRAZA was discovered and developed by Ionis and Biogen, an...

READ MORE

The US Food and Drug Administration (FDA) has given Arvelle Therapeutics’ Xcopri (cenobamate tablets) the go-ahead for partial-onset seizures in adults. The emerging company, which is part of a subsidiary of SK Biopharmaceuticals, announced that it has also licensed exclusive rights to develop and commercialise the drug in Europe, with intent to file a Marketing Authorisation Application (MAA) in the first half of next year, based on Phase II and III trials. The FDA approval was based on t...

READ MORE

Time for new pharmaceutical-innovation models. The pharmaceutical industry is one of the most profitable on earth, expected to be worth $1.4 trillion by the end of 2020. Last year, the four drug companies that dominated the vaccine market made $30 billion selling vaccines. The pharmaceutical industry benefits from considerable incentives, including in the form of patents and other market monopolies to sustain vaccine and treatment prices well above production cost. Society pays this price—...

READ MORE

Janssen has received mixed news from the UK’s cost-effectiveness watchdog for its cancer drug Imbruvica (ibrutinib). In draft guidance NICE has declined to recommend Imbruvica’s use in England and Wales to treat mantle cell lymphoma....

READ MORE

EVENTS

Vital Signs EMS Conference
VITAL SIGNS EMS CONFERENCE
October 29-01, 2020
Vital Signs EMS Conference will be showcasing many of the extraordinary aspects of EMS and healthcare found only in Saratoga Springs. This event provided high quality and cutting edge EMS education by providing access to national and world-renowned educators through a forum that is accessible and af...

Internal Medicine for Primary Care
INTERNAL MEDICINE FOR PRIMARY CARE
October 30-01, 2020
The Internal Medicine for Primary Care conference will cover areas like Internal Medicine for Primary Care Physicians, Issues in Women's Health Cardio, Pulmonary for Primary Care Physicians, Neurology for the Non-Neurologist.